Clinical Trial Update: ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections [Phase 2]

View source ↗

Summary

Phase 2 trial update for ISIS 14803-CS2 (ISIS 14803) administered IV in patients with chronic hepatitis C; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ISIS 14803-CS2 (ISIS 14803)

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Hepatitis C, Chronic | Phase 2 | Status: COMPLETED